deltatrials
Active Not Recruiting EARLY_PHASE1 NCT03493178

Glutathione in Mild Cognitive Impairment

Sponsor: Baylor College of Medicine

Conditions Mild Cognitive Impairment
Interventions Alanine Glycine N-acetylcysteine (NAC)
Updated 12 times since 2018 Last updated: Aug 21, 2025 Started: Apr 19, 2018 Primary completion: May 30, 2025 Completion: Dec 31, 2025

Listed as NCT03493178, this EARLY_PHASE1 trial focuses on Mild Cognitive Impairment and remains ongoing. Sponsored by Baylor College of Medicine, it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Nov 2024 — Sep 2025 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Nov 2024 [monthly]

    Recruiting EARLY_PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

  5. Sep 2023 — Jul 2024 [monthly]

    Recruiting EARLY_PHASE1

▶ Show 7 earlier versions

  1. Mar 2023 — Sep 2023 [monthly]

    Recruiting EARLY_PHASE1

  2. Mar 2022 — Mar 2023 [monthly]

    Recruiting EARLY_PHASE1

  3. Jan 2021 — Mar 2022 [monthly]

    Recruiting EARLY_PHASE1

  4. Jan 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

    Phase: None → EARLY_PHASE1

  5. Mar 2019 — Jan 2020 [monthly]

    Recruiting

  6. Jun 2018 — Mar 2019 [monthly]

    Recruiting

  7. May 2018 — Jun 2018 [monthly]

    Recruiting

    First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor College of Medicine
  • The Methodist Hospital Research Institute
Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States